doi:10.3390/cancers14102374engMorote, JuanBorque-Fernando, AngelTriquell, MarinaCelma, AnnaRegis, LucasMast, Richardde Torres, Inés M.Semidey, María E.Abascal, José M.Servian, PolSantamaría, AnnaPlanas, JacquesEsteban, Luis M.Trilla, EnriqueComparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate BiopsyART-2022-128599This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy.2022http://zaguan.unizar.es/record/11765210.3390/cancers14102374http://zaguan.unizar.es/record/117652oai:zaguan.unizar.es:117652info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666Cancers 14, 10 (2022), 2374 [22 pp.]byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess